Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $15.8 million.

  • Akebia Therapeutics' Change in Accured Expenses rose 60620.6% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 38323.29%. This contributed to the annual value of -$12.8 million for FY2024, which is 2750.22% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Change in Accured Expenses of $15.8 million as of Q3 2025, which was up 60620.6% from $16.0 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Change in Accured Expenses high stood at $30.8 million for Q3 2021, and its period low was -$37.2 million during Q4 2021.
  • Its 5-year average for Change in Accured Expenses is -$2.5 million, with a median of $519000.0 in 2024.
  • As far as peak fluctuations go, Akebia Therapeutics' Change in Accured Expenses tumbled by 44003.52% in 2023, and later soared by 298420.04% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Change in Accured Expenses stood at -$37.2 million in 2021, then surged by 55.7% to -$16.5 million in 2022, then soared by 122.55% to $3.7 million in 2023, then surged by 31.26% to $4.9 million in 2024, then surged by 224.59% to $15.8 million in 2025.
  • Its Change in Accured Expenses was $15.8 million in Q3 2025, compared to $16.0 million in Q2 2025 and $2.8 million in Q1 2025.